Pliant Therapeutics (PLRX) Cash & Equivalents (2019 - 2026)

Pliant Therapeutics (PLRX) has reported Cash & Equivalents for 8 consecutive years, with $22.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 75.86% year-over-year to $22.2 million; the TTM figure through Mar 2026 stood at $22.2 million (down 75.86% YoY), while the FY2025 annual figure was $45.4 million, down 36.16% from the prior year.
• Cash & Equivalents retreated to $22.2 million in Q1 2026 per PLRX's latest filing, from $45.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $114.3 million in Q1 2024 and bottomed at $22.2 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $64.7 million across 5 years, with a median of $63.2 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Equivalents jumped 215.03% — and 2026, when it slumped 75.86%.
• Pliant Therapeutics' Cash & Equivalents stood at $33.7 million in 2022, then soared by 87.72% to $63.2 million in 2023, then advanced by 12.58% to $71.2 million in 2024, then slumped by 36.16% to $45.4 million in 2025, then sank by 51.17% to $22.2 million in 2026.
• Business Quant data shows PLRX's Cash & Equivalents at $22.2 million in Q1 2026, $45.4 million in Q4 2025, and $93.7 million in Q3 2025.